PURPOSE: Bortezomib-melphalan-prednisone (VMP) has improved overall survival in multiple myeloma. This randomized trial compared VMP plus thalidomide (VMPT) induction followed by bortezomib-thalidomide maintenance (VMPT-VT) with VMP in patients with newly diagnosed multiple myeloma. PATIENTS AND METHODS: We randomly assigned 511 patients who were not eligible for transplantation to receive VMPT-VT (nine 5-week cycles of VMPT followed by 2 years of VT maintenance) or VMP (nine 5-week cycles without maintenance). RESULTS: In the initial analysis with a median follow-up of 23 months, VMPT-VT improved complete response rate from 24% to 38% and 3-year progression-free-survival (PFS) from 41% to 56% compared with VMP. In this analysis, median follow-up was 54 months. The median PFS was significantly longer with VMPT-VT (35.3 months) than with VMP (24.8 months; hazard ratio [HR], 0.58; P < .001). The time to next therapy was 46.6 months in the VMPT-VT group and 27.8 months in the VMP group (HR, 0.52; P < .001). The 5-year overall survival (OS) was greater with VMPT-VT (61%) than with VMP (51%; HR, 0.70; P = .01). Survival from relapse was identical in both groups (HR, 0.92; P = .63). In the VMPT-VT group, the most frequent grade 3 to 4 adverse events included neutropenia (38%), thrombocytopenia (22%), peripheral neuropathy (11%), and cardiologic events (11%). All of these, except for thrombocytopenia, were significantly more frequent in the VMPT-VT patients. CONCLUSION: Bortezomib and thalidomide significantly improved OS in multiple myeloma patients not eligible for transplantation.

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival / Palumbo, A; Bringhen, S; Larocca, A; Rossi, D; Di Raimondo, F; Magarotto, V; Patriarca, F; Levi, A; Benevolo, G; Vincelli, Id; Grasso, M; Franceschini, L; Gottardi, D; Zambello, R; Montefusco, V; Falcone, Ap; Omedé, P; Marasca, Roberto; Morabito, F; Mina, R; Guglielmelli, T; Nozzoli, C; Passera, R; Gaidano, G; Offidani, M; Ria, R; Petrucci, Mt; Musto, P; Boccadoro, M; Cavo, M.. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - STAMPA. - 32:(2014), pp. 634-640. [10.1200/JCO.2013.52.0023]

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival

MARASCA, Roberto;
2014

Abstract

PURPOSE: Bortezomib-melphalan-prednisone (VMP) has improved overall survival in multiple myeloma. This randomized trial compared VMP plus thalidomide (VMPT) induction followed by bortezomib-thalidomide maintenance (VMPT-VT) with VMP in patients with newly diagnosed multiple myeloma. PATIENTS AND METHODS: We randomly assigned 511 patients who were not eligible for transplantation to receive VMPT-VT (nine 5-week cycles of VMPT followed by 2 years of VT maintenance) or VMP (nine 5-week cycles without maintenance). RESULTS: In the initial analysis with a median follow-up of 23 months, VMPT-VT improved complete response rate from 24% to 38% and 3-year progression-free-survival (PFS) from 41% to 56% compared with VMP. In this analysis, median follow-up was 54 months. The median PFS was significantly longer with VMPT-VT (35.3 months) than with VMP (24.8 months; hazard ratio [HR], 0.58; P < .001). The time to next therapy was 46.6 months in the VMPT-VT group and 27.8 months in the VMP group (HR, 0.52; P < .001). The 5-year overall survival (OS) was greater with VMPT-VT (61%) than with VMP (51%; HR, 0.70; P = .01). Survival from relapse was identical in both groups (HR, 0.92; P = .63). In the VMPT-VT group, the most frequent grade 3 to 4 adverse events included neutropenia (38%), thrombocytopenia (22%), peripheral neuropathy (11%), and cardiologic events (11%). All of these, except for thrombocytopenia, were significantly more frequent in the VMPT-VT patients. CONCLUSION: Bortezomib and thalidomide significantly improved OS in multiple myeloma patients not eligible for transplantation.
2014
32
634
640
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival / Palumbo, A; Bringhen, S; Larocca, A; Rossi, D; Di Raimondo, F; Magarotto, V; Patriarca, F; Levi, A; Benevolo, G; Vincelli, Id; Grasso, M; Franceschini, L; Gottardi, D; Zambello, R; Montefusco, V; Falcone, Ap; Omedé, P; Marasca, Roberto; Morabito, F; Mina, R; Guglielmelli, T; Nozzoli, C; Passera, R; Gaidano, G; Offidani, M; Ria, R; Petrucci, Mt; Musto, P; Boccadoro, M; Cavo, M.. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - STAMPA. - 32:(2014), pp. 634-640. [10.1200/JCO.2013.52.0023]
Palumbo, A; Bringhen, S; Larocca, A; Rossi, D; Di Raimondo, F; Magarotto, V; Patriarca, F; Levi, A; Benevolo, G; Vincelli, Id; Grasso, M; Franceschini, L; Gottardi, D; Zambello, R; Montefusco, V; Falcone, Ap; Omedé, P; Marasca, Roberto; Morabito, F; Mina, R; Guglielmelli, T; Nozzoli, C; Passera, R; Gaidano, G; Offidani, M; Ria, R; Petrucci, Mt; Musto, P; Boccadoro, M; Cavo, M.
File in questo prodotto:
File Dimensione Formato  
Palumbo-JCO 2014 (VMP vs VMPT).pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 253.52 kB
Formato Adobe PDF
253.52 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1081841
Citazioni
  • ???jsp.display-item.citation.pmc??? 67
  • Scopus 193
  • ???jsp.display-item.citation.isi??? 173
social impact